A new study published in the journal Pain Management suggests that spinal cord stimulators are underutilized for ideal candidates and are often implanted too late to make functional gains. The authors explain: “Initially conceived of as a therapy of last resort, SCS has gradually acquired first-line status for the treatment of chronic neuropathic pain. There is widespread agreement amongst experts that patients presenting with neuropathic pain who do not respond to conventional treatments by 12 to 16 weeks should be offered a trial of SCS. We have demonstrated that efficacy of SCS treatment is time dependent with success rates exceeding 80% if implantation occurs within 2 years of symptom onset, compared with 15% for patients whose implants happened 20 years after the onset of pain.” One of the authors (the late Krishna Kumar) disclosed that he wasa paid consultant for Medtronic Inc. and Boston Scientific, two makers of spinal cord stimulators.
Read the study here.
Read an overview from WorkCompCentral (paid content) here.